Navigation Links
VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
Date:11/12/2007

statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

* our ability to obtain necessary financing;

* our ability to control our operating expenses;

* our ability to recruit and enroll patients for the CEA, ACS and FDG-

PET clinical trials;

* our ability to successfully complete our clinical trials of VIA-2291

on expected timetables and the outcomes of such clinical trials;

* the results of our clinical trials, including without limitation,

with respect to the safety and efficacy of VIA-2291;

* the outcome of any legal proceedings;

* our ability to obtain necessary FDA approvals;

* our ability to successfully commercialize VIA-2291;

* our ability to obtain and protect our intellectual property related

to our product candidates;

* our potential for future growth and the development of our product

pipeline;

* our ability to form and maintain collaborative relationships to

develop and commercialize our product candidates;

* general economic and business conditions; and

* the other risks described under the heading "Risk Factors" in our

Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 on

file with the SEC and in Amendment No. 3 to our Registration

Statement on Form S-3, filed with the SEC October 15, 2007.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Springfield, Mo. (PRWEB) September 30, 2014 ... participate at ISPE Boston Product Show 2014. The Boston ... has booked the 23rd annual, day-long event for Wed., ... The show promises to be the largest in ISPE ... scheduled and upward of 3,000 attendees expected. , ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... and collaboration company is dedicated to supporting business ... needs. Julie Power, a carrier services ... ensure collaboration solutions stays connected and productive at ... the increased movement of businesses to cloud communications ...
(Date:9/30/2014)... September 30, 2014 On September 11, Pharma ... Sherley in anticipation of a session that he will lead ... Summit,” scheduled for February 17-18, 2015 in London. In ... IQ asked Dr. Sherley to respond to several questions on ... challenges to evaluating stem cell toxicity, and future trends in ...
(Date:9/30/2014)... Jersey (PRWEB) September 30, 2014 ... has been chosen by the Parenteral Drug Association ... 18 and 19, 2014) on container closure integrity testing. ... closure integrity test methods and philosophies detailed in the ... Integrity Evaluation. The course will span container ...
Breaking Biology Technology:HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3SoundConnect Expands Carrier Services Division 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4
... the appointment of James Stoppert as President and Chief Executive Officer ... ... EON) September 3, 2008 -- Segetis is the first and ... wide range of industrial chemicals and plastics that are ultimately derived ...
... China, Sept. 3 ,Acesys Pharmatech and Provid Pharmaceuticals ... expertise and project management,capabilities of Provid in the ... structure of Acesys in China., The combined ... of medicinal chemistry for clients in the pharmaceutical ...
... tested new molecular tools for stem cell research to direct ... development programmes. , A collaborative team of scientists from ... (NESCI) have developed two synthetic molecules which can be used ... into other forms of tissue. , Their use ...
Cached Biology Technology: Stoppert Named as President and CEO at Breakthrough Renewable Technology Firm Segetis, Inc 2Acesys and Provid Announce Alliance for Medicinal Chemistry Services 2New stem cell tools to aid drug development 2New stem cell tools to aid drug development 3
(Date:9/30/2014)... German . ... risky situations such as exposure to predators. Researchers from ... a long-term study on different populations of great tits ... ambient temperature. High metabolic rates and low temperatures were ... birds were more likely to approach potential predators. , ...
(Date:9/30/2014)... Coral reefs face a suite of perilous threats ... coastal development and climate change, fragile coral ecosystems ... Despite this trend, some species of corals surrounding ... a natural protector in their tropical environment: coral ... Natural History,s Smithsonian Marine Station scientist Seabird McKeon ...
(Date:9/30/2014)... -- Winners of The Economist,s prestigious Innovation awards 2014 ... place at the JW Marriott Hong Kong on Friday, October 10 ... their experiences and the lessons those hold for others. The awards, ... the past decade, will be presented at a ceremony in ... will be the first time the ceremony has come to ...
Breaking Biology News(10 mins):Risky metabolism 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... like AND and OR Boolean logic gates, producing an output ... in the May issue of Nature Chemical Biology , ... tiny circuits. Study leader Takanari Inoue, Ph.D., an assistant ... the Institute of Basic Biomedical Sciences, Center for Cell Dynamics ...
... of published studies on the impact of bark beetles ... more complete picture of the effect of this destructive ... a wide variety ofand often contradictoryconclusions about the bark ... researchers from the USDA Forest Service,s Pacific Southwest Research ...
... Calif.) Synthetic platelets have been developed by UC ... Research Institute and Sanford-Burnham Institute in La Jolla, Calif. ... Materials in a paper titled "Platelet Mimetic Particles ... the components of blood that allow it to prevent ...
Cached Biology News:Training cells to perform Boolean functions? It's logical 2Training cells to perform Boolean functions? It's logical 3New report examines effects of trees killed by bark beetles on wildfire 2UC Santa Barbara researchers develop synthetic platelets 2
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
... ICE-LAP3 Mch3 ... study of enzyme regulation and kinetics, cleavage of target ... 15,000 units/mg protein. One unit is defined ... nmol of Ac-DEVD-pNA Cat. No. 235400 per hour at ...
Request Info...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Biology Products: